Crescita Therapeutics Inc News - CTX | Aktien Toronto Börse

Crescita Reports Q4 and Fiscal 2024 Results

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports Third Quarter 2024 Results

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports Second Quarter 2024 Results

Secures Manufacturing Contract of US$10 Million over 4 Years Completes Strategic Asset Acquisition Crescita Therapeutics Inc. (TSX: CTX and...

Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Completes Acquisition of Strategic Assets of Occy Laboratory

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita to Acquire Strategic Assets of Occy Laboratory

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports First Quarter 2024 Results

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports Q4 and Fiscal 2023 Results

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports Third Quarter 2023 Results

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Crescita Therapeutics Inc (CTX)

Professionelle Tools für Privatanleger.

CTX Nachrichten

Crescita Reports Q4 and Fiscal 2024 Results

Crescita Reports Third Quarter 2024 Results

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024

Crescita Reports Second Quarter 2024 Results

Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years

Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement

Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device

Crescita Completes Acquisition of Strategic Assets of Occy Laboratory

Crescita to Acquire Strategic Assets of Occy Laboratory

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Reports First Quarter 2024 Results

Crescita Reports Q4 and Fiscal 2023 Results

Crescita Reports Third Quarter 2023 Results

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

CTX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Crescita Therapeutics Inc (CTX) News

Crescita Therapeutics Inc (CTX)

Professionelle Tools für Privatanleger.

CTX Nachrichten

Crescita Reports Q4 and Fiscal 2024 Results

Crescita Reports Third Quarter 2024 Results

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024

Crescita Reports Second Quarter 2024 Results

Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years

Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement

Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device

Crescita Completes Acquisition of Strategic Assets of Occy Laboratory

Crescita to Acquire Strategic Assets of Occy Laboratory

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Reports First Quarter 2024 Results

Crescita Reports Q4 and Fiscal 2023 Results

Crescita Reports Third Quarter 2023 Results

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

CTX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen